on Nanohale AG (ETR:FYB)
Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization
Formycon AG has announced partnerships with Actor Pharmaceuticals and Megalabs for the commercialization of its Eylea® biosimilar FYB203 in Australia and Latin America. The agreements, managed by Klinge Biopharma GmbH, involve upfront and milestone payments, alongside royalties on sales. Formycon will support the supply chain for FYB203 and receive additional service payments.
The aflibercept-based biosimilar FYB203 has received approvals from the FDA, European Commission, and MHRA. In Australia, the product awaits regulatory approval from the Therapeutic Goods Administration. Authorizations in Latin America are in progress with Megalabs.
Eylea® treats severe retinal diseases, including neovascular age-related macular degeneration, by inhibiting VEGF-induced blood vessel formation.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news